Post v. Avita Drugs, LLC

2017 NCBC 93
CourtNorth Carolina Business Court
DecidedOctober 11, 2017
Docket17-CVS-798
StatusPublished
Cited by1 cases

This text of 2017 NCBC 93 (Post v. Avita Drugs, LLC) is published on Counsel Stack Legal Research, covering North Carolina Business Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Post v. Avita Drugs, LLC, 2017 NCBC 93 (N.C. Super. Ct. 2017).

Opinion

Post v. Avita Drugs, LLC, 2017 NCBC 93.

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE SUPERIOR COURT DIVISION ROWAN COUNTY 17 CVS 798

DAVID B. POST, Individually and as Sellers’ Representative,

Plaintiff,

v. ORDER AND OPINION ON DEFENDANT’S MOTION TO DISMISS AVITA DRUGS, LLC, a Louisiana limited liability company,

Defendant.

1. This dispute arises out of the sale of Plaintiff David Post’s business,

MedExpress Pharmacy, Ltd. (“MedExpress”), to Defendant Avita Drugs, LLC

(“Avita”) in 2014. Post contends that Avita breached the parties’ Stock Purchase

Agreement and, in doing so, committed unfair or deceptive trade practices under N.C.

Gen. Stat. § 75-1.1. Avita moves to dismiss the claim for unfair or deceptive trade

practices pursuant to Rule 12(b)(6) of the North Carolina Rules of Civil Procedure.

Having considered the parties’ filings and arguments, the Court GRANTS the motion

to dismiss.

Robinson, Bradshaw & Hinson, P.A., by Edward F. Hennessey, IV and Adam K. Doerr, for Plaintiff.

Moore & Van Allen PLLC, by Valecia M. McDowell and E. Taylor Stukes, and Andrews Kurth Kenyon LLP, by William J. Moore, for Defendant.

Conrad, Judge. I. BACKGROUND

2. The Court does not make findings of fact on a Rule 12(b)(6) motion to

dismiss. The following factual summary is drawn from relevant allegations in the

complaint and the contract that is the subject of the complaint.

3. Formed in 2001, MedExpress is a “retail and specialty pharmacy serving

customers both from its physical location and by delivery.” (Compl. ¶¶ 1, 6, ECF No.

1.) MedExpress’s rapid growth attracted a measure of publicity, and during 2013 and

2014, Post and MedExpress’s two other shareholders entertained offers from Avita

and a second bidder to purchase the company. (Compl. ¶¶ 6–10.) After Avita

sweetened its offer, a deal was struck. (Compl. ¶¶ 11–13.)

4. In a Stock Purchase Agreement (“SPA”) dated June 30, 2014, Avita acquired

all outstanding shares of common stock in MedExpress. (See Compl. ¶ 18; Notice of

Filing Ex. A, ECF No. 33 [“SPA”].) Avita agreed to pay more than $6 million in cash

at closing plus a “deferred payment” of an “Earnout Amount” not to exceed $5.5

million. (Compl. ¶ 19; SPA §§ 2.01, 2.06(a)(vii), (d)(i).) The Earnout Amount, which

is contingent on MedExpress’s performance after the sale, is the subject of this

litigation.

5. The formula for calculating the Earnout Amount is a simple equation: “six

times (6x) the difference between: (a) Adjusted EBITDA; and (b) $925,000.” (Compl.

¶ 21; SPA § 2.06(a)(vii).) Adjusted EBITDA, the key variable, is defined as

MedExpress’s “earnings from operations before interest, taxes, depreciation and

amortization” during the one-year period after the sale, as calculated according to Generally Accepted Accounting Principles and adjusted to exclude various

enumerated amounts. (SPA § 2.06(a)(i).) Due to the multiplier, small variations in

the Adjusted EBITDA calculation markedly affect the Earnout Amount: each dollar

added to Adjusted EBITDA increases the Earnout Amount by six dollars, and each

dollar subtracted takes six away.

6. Anticipating disagreements, the SPA laid out a process for calculating the

Earnout Amount and resolving certain disputes. Avita was required to compute

Adjusted EBITDA at the end of the one-year period and to provide a written

explanation to Post. (SPA § 2.06(d)(i).) That calculation triggered a 30-day window

for Post to lodge an objection, followed by a second 30-day period for negotiation to

resolve the objection. (SPA § 2.06(d)(ii).) In the event of an impasse, the parties were

to submit the “determination of Adjusted EBITDA” to an independent accountant for

a “binding and conclusive” resolution. (SPA § 2.06(d)(ii).)

7. Each side also negotiated for substantive protections. Post retained the

right to review MedExpress’s financial reports on a monthly basis, (SPA

§ 2.06(c)(vii)), and he secured covenants in which Avita promised not to use its

corporate control over the company to manipulate the performance metrics, (see

Compl. ¶ 23). Among other things, Avita agreed to operate MedExpress “as a

separate corporation,” not to “intentionally divert any profitable business

opportunity” to itself, and not to enter into transactions “with the primary intent of

adversely affecting Adjusted EBITDA.” (SPA § 2.06(e)(i)–(vi).) 8. For its part, Avita obtained indemnification rights against the selling

shareholders. (SPA §§ 9.01, 9.02, 9.05.) And it reserved the “right to set-off against,

or reduce the Earnout Amount by any damages resulting from” Post’s breach of any

representations and warranties in the SPA. (SPA § 9.07.)

9. Within a few months of the sale, Avita began exercising these rights. As

early as September 2014, Avita asserted claims against Post under Sections 9.02 and

9.05 of the SPA. (See Compl. ¶ 24.) In July 2015, Avita notified Post that the amount

of these claims could exceed the Earnout Amount. (See Compl. ¶ 28.) Post alleges

that the claims were “spurious,” “contrived,” and designed to depress the Earnout

Amount and to be used as “negotiating chips” in any dispute over its calculation.

(Compl. ¶¶ 27–31.)

10. On August 14, 2015, Avita informed Post that it had calculated the Earnout

Amount to be $1,542,283. (See Compl. ¶ 32.) Avita also stated that it would “hold

back the Earnout Amount” pending its investigations of the claims asserted against

Post. (Compl. ¶ 32.)

11. Post “timely objected to Avita’s determination.” (Compl. ¶ 33.) In response,

Avita revised the Earnout Amount to $1,900,075—an amount that, though increased,

did not satisfy Post’s objections. (See Compl. ¶ 33.) Avita has not yet tendered any

payment. (See Compl. ¶¶ 32–33.)

12. After acquiring the other shareholders’ rights under the SPA, (see Compl.

¶ 20), Post filed this action on April 3, 2017. The complaint alleges numerous

breaches of the SPA, alleges unfair or deceptive trade practices under N.C. Gen. Stat. § 75-1.1, and seeks a declaratory judgment as to the Earnout Amount. In short, Post

asserts that Avita took a series of actions to depress the Adjusted EBITDA

calculation, including using improper accounting practices, (Compl. ¶¶ 39–40);

making retroactive adjustments to MedExpress’s books and records, (Compl. ¶¶ 37–

38); and failing to operate MedExpress as a separate company while transferring

customers and contracts to itself, (see Compl. ¶ 41).

13. On June 29, 2017, Avita moved to dismiss the section 75-1.1 claim. On

August 1, 2017, Post filed his response. During briefing, the parties also reached an

agreement to submit certain disputes regarding the determination of Adjusted

EBITDA to an independent accountant as required by the SPA.

14. The motion is fully briefed, and the Court held a hearing on August 16, 2017,

at which all parties were represented by counsel. The motion is ripe for

determination.

II. ANALYSIS

15. Avita seeks to dismiss Post’s claim for unfair or deceptive trade practices on

two independent grounds. It argues, first, that the parties chose Delaware law to

govern disputes arising out of the SPA, which bars Post from maintaining a section

75-1.1 action under North Carolina law. Post responds that Delaware law governs

only the interpretation and enforcement of the SPA but North Carolina law governs

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
2017 NCBC 93, Counsel Stack Legal Research, https://law.counselstack.com/opinion/post-v-avita-drugs-llc-ncbizct-2017.